Sidley advised Nektar Therapeutics (Nasdaq:NKTR) on a global strategic development and commercialization collaboration with Bristol-Myers Squibb Company (NYSE:BMY) for Nektar’s CD122-biased agonist, NKTR-214. Bristol-Myers Squibb Company…
Nektar Therapeutics’s Collaboration agreement with Bristol-Myers Squibb
![](https://globallegalchronicle.com/wp-content/uploads/2018/03/52ac397f66.jpeg)